

PATIENT EDUCATION

JEANNINE M. BRANT, RN, MS, AOCN®
ASSOCIATE EDITOR

Radical Prostatectomy: What You Need to Know

Dawn Camp-Sorrell, MSN, FNP, AOCN®

ave you developed a patient education tool that is effective in your practice? If so, consider writing for this column dedicated to different examples of patient education tools. For more information, contact Associate Editor Jeannine M. Brant, RN, MS, AOCN®, via e-mail at jeannine.brant@svh-mt.org.

One of the most important issues in men's health today is prostate cancer. It is the most common male cancer and the second-leading cause of death among American men (American Cancer Society, 2005). Treatment options for prostate cancer vary depending on the stage at diagnosis, grade of tumor, and patient's age and functional status. One option for localized and well-differentiated tumors is radical prostatectomy (see Figure 1) with the goal of curing the disease while maintaining a man's quality of life (Shah, Robbins, Melamed, & Lepor, 2003). If prostate cancer is discovered and treated early, the overall survival rate is high.

Radical prostatectomy is the complete removal of the prostate gland, seminal vesicles, and prostatic capsule followed by surgical repair of the bladder and remaining urethra.

T1a, T1b, T1c, T2a, T2b, and T2c Radical prostatectomy, radiation therapy, or watchful waiting

T3 and T4

Radiation therapy alone or combination androgen ablation

FIGURE 1. LOCALIZED PROSTATE CANCER TREATMENT OPTIONS

The surgery can be performed with a retropubic or perineal approach and includes a sampling of the retroperitoneal lymph nodes for pathology. Patients may not be aware of the details surrounding the surgery without education from healthcare providers; therefore, the purpose of this article is to provide an educational tool, written at a basic reading level, for distribution to patients undergoing radical prostatectomy.

The author would like to thank Becca Hawkins, MSN, ANP, AOCN®, and Kerri Weingard, ANP-C, MS, OCN®, for reviewing this article. She also thanks her husband, who has been free of prostate cancer for two and a half years, for his input.

Author Contact: Dawn Camp-Sorrell, MSN, FNP, AOCN®, can be reached at onpdawn@aol.com, with copy to editor at CJONeditor@jsobel.com.

References

American Cancer Society. (2005). *Cancer facts and figures 2005*. Atlanta, GA: Author.

Shah, O., Robbins, D.A., Melamed, J., & Lepor, H. (2003). The New York University nerve sparing algorithm decreases the rate of positive surgical margins following radical retropubic prostatectomy. *Journal of Urology*, 169, 2147–2152.

Bibliography

D'Amico, A.V., Moul, J., Carroll, P.R., Sun, L., Lubeck, D., & Chen, M.H. (2003). Cancerspecific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. *Journal of Clinical Oncology*, 21, 2163–2172.

Korda, M. (1996). *Man to man: Surviving prostate cancer.* New York: Random House.

Lepor, H. (2003). Practical considerations in radical retropubic prostatectomy. *Urologic Clinics* of North America, 30, 363–368.

Linton, K.D., & Hamdy, F.C. (2003). Early diagnosis and surgical management of prostate cancer. Cancer Treatment Review, 29, 151–160.

Marshke, P.S. (2001). The role of surgery in the treatment of prostate cancer. Seminars in Oncology Nursing, 17, 85–89.

Masters, J.G., & Rice, M.L. (2003). Improvement in urinary symptoms after radical prostatectomy: A prospective evaluation of flow rates and symptom scores. *British Journal of Urol*ogy, 91, 795–797.

O'Rourke, M.E. (2001). Decision making and prostate cancer treatment selection: A review. Seminars in Oncology Nursing, 17, 108–117.

Palmer, M.H., Fogarty, L.A., Somerfield, M.R., & Powell, L.L. (2003). Incontinence after prostatectomy: Coping with incontinence after prostate cancer surgery. *Oncology Nursing Forum*, 30, 229–238.

Dawn Camp-Sorrell, MSN, FNP, AOCN®, is an oncology nurse practitioner at Hematology and Oncology Associates of Alabama, LLC, in Sylacauga.

Digital Object Identifier: 10.1188/05.CJON.378-380